psychiatryПСИХИАТРИЯPsychiatry (Moscow) (Psikhiatriya)1683-83192618-6667FSBSI “The Mental Health Research Centre”; LLC «Publisher «MIA»10.30629/2618-6667-2024-22-5-94-106psychiatry-1253Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSКреатин-креатинфосфатная система в норме и при психических заболеванияхCreatine – Creatine Phosphate System in Healthy Persons and in Patients with Mental Disordershttps://orcid.org/0000-0001-7744-533XБурбаеваГ. Ш.BurbaevaG. Sh.

Гульнур Шингожиевна Бурбаева, доктор биологических наук, профессор, главный научный сотруднк, лаборатория нейрохимии

Москва

Gulnur Sh. Burbaeva, Professor, Dr. Sci. (Biol.), Chief Researcher, Neurochemistry Laboratory

Moscow

gburb@mail.ruhttps://orcid.org/0000-0003-1369-8658БокшаИ. С.BokshaI. S.

Ирина Сергеевна Бокша, доктор биологических наук, главный научный сотрудник, лаборатория нейрохимии

Москва

Irina S. Boksha, Dr. Sci. (Biol.), Chief Researcher, Neurochemistry Laboratory

Moscow

boksha_irina@mail.ruhttps://orcid.org/0000-0002-5996-6606СавушкинаО. К.SavushkinaO. K.

Ольга Константиновна Савушкина, кандидат биологических наук, исполняющий обязанности заведующего лабораторией, ведущий научный сотрудник, лаборатория нейрохимии

Москва

Olga K. Savushkina, Cand. Sci. (Biol.), Acting Head of Laboratory, Neurochemistry Laboratory

Moscow

osavushkina1@yandex.ruhttps://orcid.org/0000-0002-3574-2165ПрохороваТ. А.ProkhorovaT. A.

Татьяна Андреевна Прохорова, научный сотрудник, лаборатория нейрохимии

Москва

Tatyana A. Prokhorova, Researcher, Laboratory of Neurochemistry

Moscow

gnidra@mail.ruhttps://orcid.org/0000-0002-4784-8995ТерешкинаЕ. Б.TereshkinaE. B.

Елена Борисовна Терешкина, кандидат биологических наук, старший научный сотрудник, лаборатория нейрохимии

Москва

Elena B. Tereshkina, Cand. of Sci. (Biol.), Senior researcher, Laboratory of Neurochemistry

Moscow

tereshkina.el@yandex.ruhttps://orcid.org/0000-0002-5766-0910ВоробьёваЕ. А.VorobyevaE. A.

Елена Анатольевна Воробьёва, кандидат биологических наук, научный сотрудник, лаборатория нейрохимии

Москва

Elena A. Vorobyeva, Cand. of Sci. (Biol.), Researcher, Laboratory of Neurochemistry

Moscow

vaa-vea-@yandex.ruФГБНУ «Научный центр психического здоровья»РоссияFederal State Budgetary Institution “Mental Health Research Centre”Russian Federation20240901202522594106Copyright © Бурбаева Г.Ш., Бокша И.С., Савушкина О.К., Прохорова Т.А., Терешкина Е.Б., Воробьёва Е.А., 20252025Бурбаева Г.Ш., Бокша И.С., Савушкина О.К., Прохорова Т.А., Терешкина Е.Б., Воробьёва Е.А.Burbaeva G.S., Boksha I.S., Savushkina O.K., Prokhorova T.A., Tereshkina E.B., Vorobyeva E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.journalpsychiatry.com/jour/article/view/1253

Обоснование: для нормального функционирования мозга необходима система поддержания пулов и равновесия концентраций основных макроэргических соединений — АТФ и креатинфосфата (КрФ). Ее основные компоненты — это креатин (Кр), креатинфосфат (КрФ) и креатинфосфокиназа (КФК, или креатинкиназа), катализирующая реакцию переноса высокоэнергетического фосфорного остатка между АТФ, Кр и КрФ. Цель обзора — провести анализ результатов исследований элементов Кр — КрФ системы: Кр, КрФ и КФК при психических и нейродегенеративных расстройствах и рассмотреть возможности использования Кр — КрФ-ориентированной терапии психических и нейродегенеративных расстройств. Методы: по сочетаниям ключевых слов «креатин», «креатинфосфат», «креатинкиназа», «шизофрения», «биполярное аффективное расстройство», «болезнь Альцгеймера», «фармакотерапия» проведен поиск источников по базам данных Medline/PubMed, Scopus и РИНЦ. Заключение: критическое рассмотрение оригинальных статей, как клинических, так и экспериментальных, включая исследования, выполненные на моделях животных, дает веское основание считать подтвержденной вовлеченность Кр — КрФ системы в патогенез психических заболеваний и открывает дальнейшие перспективы Кр — КрФ-ориентированной терапии психических и нейродегенеративных расстройств, однако необходимо проведение дальнейших клинических исследований Кр — КрФ системы в психиатрии.

Background: the normal brain functioning is provided by a brain system maintaining pools and balance of concentrations of the main high-energy compounds, such as ATP and creatine phosphate (CrP), with its main components — creatine (Cr), creatine phosphate (CrP) and creatine phosphokinase (or creatine kinase, CK), the last is catalyzing the reaction of high-energy phosphate residue transfer between ATP, Cr and CrP. The purpose of this review is to analyze the results of studies on the elements of the Cr — CrP system: Cr, CrP and CK in healthy persons and in patients with mental and neurodegenerative disorders and to consider the possibilities of using Cr — CrP-targeted therapy for mental and neurodegenerative disorders. Methods: using combinations of keywords “creatine”, “creatine phosphate”, “creatine kinase”, “schizophrenia”, “bipolar affective disorder”, “Alzheimer’s disease” and “pharmacotherapy”, a search was conducted for sources in the Medline/PubMed, Scopus and RSCI databases. Conclusion: a critical examination of the original articles, both clinical and experimental, including studies performed on animal models, provides a good reason to believe that the involvement of the Cr — CrP system in the pathogenesis of mental illnesses has been confirmed and opens up further prospectives for Cr — CrP-oriented therapy of mental and neurodegenerative disorders, however, further clinical studies of the Cr — CrP system in psychiatry are necessary.

креатинкреатинфосфаткреатинфосфокиназашизофрениябиполярное аффективное расстройствоболезнь Альцгеймераcreatinecreatine phosphatecreatine phosphokinaseschizophreniabipolar affective disorderAlzheimer’s diseaseReferencesMaly IV, Morales MJ, Pletnikov MV. Astrocyte Bioenergetics and Major Psychiatric Disorders. Adv Neurobiol. 2021;26:173-227. doi: 10.1007/978-3-030-77375-5Maly IV, Morales MJ, Pletnikov MV. Astrocyte Bioenergetics and Major Psychiatric Disorders. Adv Neurobiol. 2021;26:173-227. doi: 10.1007/978-3-030-77375-5Бокша ИС, Прохорова ТА, Савушкина ОК, Терешкина ЕБ, Воробьева ЕА, Бурбаева ГШ. Аномалии энергетического метаболизма при шизофрении и возможные патогенетически-ориентированные терапевтические подходы. Нейрохимия. 2023;40(4):406-422. doi: 10.31857/S1027813323040088.Boksha IS, Prokhorova TA, Savushkina OK, Tereshkina EB, Vorobyeva EA, Burbaeva GS. Anomalies of Energy Metabolism in Schizophrenia and Possible Pathogenetic-Targeted Therapeutic Approaches. Neurochem J. 2023;17:676-690. doi: 10.1134/S1819712423040086Meftahi GH, Hatef B, Pirzad Jahromi G. Creatine Activity as a Neuromodulator in the Central Nervous System. Arch Razi Inst. 2023; 78(4):1169-1175. doi: 10.32592/ARI.2023.78.4.1169Meftahi GH, Hatef B, Pirzad Jahromi G. Creatine Activity as a Neuromodulator in the Central Nervous System. Arch Razi Inst. 2023; 78(4):1169-1175. doi: 10.32592/ARI.2023.78.4.1169Cunha MP, Lieberknecht V, Ramos-Hryb AB, Olescowicz G, Ludka FK, Tasca CI, Gabilan NH, Rodrigues AL. Creatine affords protection against glutamate-induced nitrosative and oxidative stress. Neurochem Int. 2016;95:4-14. doi: 10.1016/j.neuint.2016.01.002Cunha MP, Lieberknecht V, Ramos-Hryb AB, Olescowicz G, Ludka FK, Tasca CI, Gabilan NH, Rodrigues AL. Creatine affords protection against glutamate-induced nitrosative and oxidative stress. Neurochem Int. 2016;95:4-14. doi: 10.1016/j.neuint.2016.01.002Genius J, Geiger J, Bender A, Möller HJ, Klopstock T, Rujescu D. Creatine protects against excitoxicity in an in vitro model of neurodegeneration. PLoS One. 2012;7(2):e30554. doi: 10.1371/journal.pone.0030554Genius J, Geiger J, Bender A, Möller HJ, Klopstock T, Rujescu D. Creatine protects against excitoxicity in an in vitro model of neurodegeneration. PLoS One. 2012;7(2):e30554. doi: 10.1371/journal.pone.0030554Rambo LM, Ribeiro LR, Schramm VG, Berch AM, Stamm DN, Della-Pace ID, Silva LF, Furian AF, Oliveira MS, Fighera MR, Royes LF. Creatine increases hippocampal Na(+ ),K(+ )-ATPase activity via NMDA-calcineurin pathway. Brain Res Bull. 2012;88(6):553-559. doi: 10.1016/j.brainresbull.2012.06.007Rambo LM, Ribeiro LR, Schramm VG, Berch AM, Stamm DN, Della-Pace ID, Silva LF, Furian AF, Oliveira MS, Fighera MR, Royes LF. Creatine increases hippocampal Na(+ ),K(+ )-ATPase activity via NMDA-calcineurin pathway. Brain Res Bull. 2012;88(6):553-559. doi: 10.1016/j.brainresbull.2012.06.007Cunha MP, Pazini FL, Ludka FK, Rosa JM, Oliveira Á, Budni J, Ramos-Hryb AB, Lieberknecht V, Bettio LE, Martín-de-Saavedra MD, López MG, Tasca CI, Rodrigues AL. The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. Amino Acids. 2015 Apr;47(4):795-811. doi: 10.1007/s00726-014-1910-0Cunha MP, Pazini FL, Ludka FK, Rosa JM, Oliveira Á, Budni J, Ramos-Hryb AB, Lieberknecht V, Bettio LE, Martín-de-Saavedra MD, López MG, Tasca CI, Rodrigues AL. The modulation of NMDA receptors and L-arginine/nitric oxide pathway is implicated in the anti-immobility effect of creatine in the tail suspension test. Amino Acids. 2015 Apr;47(4):795-811. doi: 10.1007/s00726-014-1910-0Souza MA, Magni DV, Guerra GP, Oliveira MS, Furian AF, Pereira L, Marquez SV, Ferreira J, Fighera MR, Royes LF. Involvement of hippocampal CAMKII/CREB signaling in the spatial memory retention induced by creatine. Amino Acids. 2012;43(6):2491-2503. doi: 10.1007/s00726-012-1329-4Souza MA, Magni DV, Guerra GP, Oliveira MS, Furian AF, Pereira L, Marquez SV, Ferreira J, Fighera MR, Royes LF. Involvement of hippocampal CAMKII/CREB signaling in the spatial memory retention induced by creatine. Amino Acids. 2012;43(6):2491-2503. doi: 10.1007/s00726-012-1329-4Gerbatin RR, Silva LFA, Hoffmann MS, Della-Pace ID, do Nascimento PS, Kegler A, de Zorzi VN, Cunha JM, Botelho P, Neto JBT, Furian AF, Oliveira MS, Fighera MR, Royes LFF. Delayed creatine supplementation counteracts reduction of GABAergic function and protects against seizures susceptibility after traumatic brain injury in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:328-338. doi: 10.1016/j.pnpbp.2019.02.004Gerbatin RR, Silva LFA, Hoffmann MS, Della-Pace ID, do Nascimento PS, Kegler A, de Zorzi VN, Cunha JM, Botelho P, Neto JBT, Furian AF, Oliveira MS, Fighera MR, Royes LFF. Delayed creatine supplementation counteracts reduction of GABAergic function and protects against seizures susceptibility after traumatic brain injury in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2019;92:328-338. doi: 10.1016/j.pnpbp.2019.02.004Andres RH, Huber AW, Schlattner U, Pérez-Bouza A, Krebs SH, Seiler RW, Wallimann T, Widmer HR. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience. 2005;133(3):701-713. doi: 10.1016/j.neuroscience.2005.03.004Andres RH, Huber AW, Schlattner U, Pérez-Bouza A, Krebs SH, Seiler RW, Wallimann T, Widmer HR. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue. Neuroscience. 2005;133(3):701-713. doi: 10.1016/j.neuroscience.2005.03.004Cunha MP, Pazini FL, Oliveira Á, Machado DG, Rodrigues AL. Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice. Brain Res Bull. 2013;95:61-69. doi: 10.1016/j.brainresbull.2013.01.005Cunha MP, Pazini FL, Oliveira Á, Machado DG, Rodrigues AL. Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice. Brain Res Bull. 2013;95:61-69. doi: 10.1016/j.brainresbull.2013.01.005Bian X, Zhu J, Jia X, Liang W, Yu S, Li Z, Zhang W, Rao Y. Suggestion of creatine as a new neurotransmitter by approaches ranging from chemical analysis and biochemistry to electrophysiology. Elife. 2023;12:RP89317. doi: 10.7554/eLife.89317Bian X, Zhu J, Jia X, Liang W, Yu S, Li Z, Zhang W, Rao Y. Suggestion of creatine as a new neurotransmitter by approaches ranging from chemical analysis and biochemistry to electrophysiology. Elife. 2023;12:RP89317. doi: 10.7554/eLife.89317Béard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. J Neurochem. 2010;115(2):297-313. doi: 10.1111/j.1471-4159.2010.06935.xBéard E, Braissant O. Synthesis and transport of creatine in the CNS: importance for cerebral functions. J Neurochem. 2010;115(2):297-313. doi: 10.1111/j.1471-4159.2010.06935.xSnow RJ, Murphy RM. Creatine and the creatine transporter: a review. Mol Cell Biochem. 2001;224(1– 2):169–181. doi: 10.1023/a:1011908606819Snow RJ, Murphy RM. Creatine and the creatine transporter: a review. Mol Cell Biochem. 2001;224(1– 2):169–181. doi: 10.1023/a:1011908606819Ohtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K, Terasaki T. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab. 2002;22(11):1327-1335. doi: 10.1097/01.WCB.0000033966.83623.7DOhtsuki S, Tachikawa M, Takanaga H, Shimizu H, Watanabe M, Hosoya K, Terasaki T. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J Cereb Blood Flow Metab. 2002;22(11):1327-1335. doi: 10.1097/01.WCB.0000033966.83623.7DBraissant O, Henry H, Béard E, Uldry J. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. Amino Acids. 2011;40(5):1315-1324. doi: 10.1007/s00726-011-0852-zBraissant O, Henry H, Béard E, Uldry J. Creatine deficiency syndromes and the importance of creatine synthesis in the brain. Amino Acids. 2011;40(5):1315-1324. doi: 10.1007/s00726-011-0852-zMak CS, Waldvogel HJ, Dodd JR, Gilbert RT, Lowe MT, Birch NP, Faull RL, Christie DL. Immunohistochemical localisation of the creatine transporter in the rat brain. Neuroscience. 2009;163(2):571–585. doi: 10.1016/j.neuroscience.2009.06.065Mak CS, Waldvogel HJ, Dodd JR, Gilbert RT, Lowe MT, Birch NP, Faull RL, Christie DL. Immunohistochemical localisation of the creatine transporter in the rat brain. Neuroscience. 2009;163(2):571–585. doi: 10.1016/j.neuroscience.2009.06.065van der Hart MG, Czéh B, de Biurrun G, Michaelis T, Watanabe T, Natt O, Frahm J, Fuchs E. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry. 2002;7(9):933-941. doi: 10.1038/sj.mp.4001130van der Hart MG, Czéh B, de Biurrun G, Michaelis T, Watanabe T, Natt O, Frahm J, Fuchs E. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol Psychiatry. 2002;7(9):933-941. doi: 10.1038/sj.mp.4001130Knox D, Perrine SA, George SA, Galloway MP, Liberzon I. Single prolonged stress decreases glutamate, glutamine, and creatine concentrations in the rat medial prefrontal cortex. Neurosci Lett. 2010;480(1):16-20. doi: 10.1016/j.neulet.2010.05.052Knox D, Perrine SA, George SA, Galloway MP, Liberzon I. Single prolonged stress decreases glutamate, glutamine, and creatine concentrations in the rat medial prefrontal cortex. Neurosci Lett. 2010;480(1):16-20. doi: 10.1016/j.neulet.2010.05.052Volz HR, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, Holstein W, Czekalla J, Sauer H. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study. Biol Psychiatry. 2000;47(11):954-961. doi: 10.1016/s0006-3223(00)00235-3Volz HR, Riehemann S, Maurer I, Smesny S, Sommer M, Rzanny R, Holstein W, Czekalla J, Sauer H. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study. Biol Psychiatry. 2000;47(11):954-961. doi: 10.1016/s0006-3223(00)00235-3Klemm S, Rzanny R, Riehemann S, Volz HP, Schmidt B, Gerhard UJ, Filz C, Schönberg A, Mentzel HJ, Kaiser WA, Blanz B. Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia. Am J Psychiatry. 2001;158(6):958-960. doi: 10.1176/appi.ajp.158.6.958Klemm S, Rzanny R, Riehemann S, Volz HP, Schmidt B, Gerhard UJ, Filz C, Schönberg A, Mentzel HJ, Kaiser WA, Blanz B. Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia. Am J Psychiatry. 2001;158(6):958-960. doi: 10.1176/appi.ajp.158.6.958Jayakumar PN, Gangadhar BN, Venkatasubramanian G, Desai S, Velayudhan L, Subbakrishna D, Keshavan MS. High energy phosphate abnormalities normalize after antipsychotic treatment in schizophrenia: a longitudinal 31P MRS study of basal ganglia. Psychiatry Res. 2010;181(3):237-240. doi: 10.1016/j.pscychresns.2009.10.010Jayakumar PN, Gangadhar BN, Venkatasubramanian G, Desai S, Velayudhan L, Subbakrishna D, Keshavan MS. High energy phosphate abnormalities normalize after antipsychotic treatment in schizophrenia: a longitudinal 31P MRS study of basal ganglia. Psychiatry Res. 2010;181(3):237-240. doi: 10.1016/j.pscychresns.2009.10.010Yuksel C, Chen X, Chouinard VA, Nickerson LD, Gardner M, Cohen T, Öngür D, Du F. Abnormal Brain Bioenergetics in First-Episode Psychosis. Schizophr Bull Open. 2021;2(1):sgaa073. doi: 10.1093/schizbullopen/sgaa073Yuksel C, Chen X, Chouinard VA, Nickerson LD, Gardner M, Cohen T, Öngür D, Du F. Abnormal Brain Bioenergetics in First-Episode Psychosis. Schizophr Bull Open. 2021;2(1):sgaa073. doi: 10.1093/schizbullopen/sgaa073Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res. 2007;41(8):625-634. doi: 10.1016/j.jpsychires.2006.07.002Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, Rothermundt M, Arolt V, Heindel W, Pfleiderer B. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res. 2007;41(8):625-634. doi: 10.1016/j.jpsychires.2006.07.002Ongür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009;172(1):44-48. doi: 10.1016/j.pscychresns.2008.06.002Ongür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009;172(1):44-48. doi: 10.1016/j.pscychresns.2008.06.002Yoo SY, Yeon S, Choi CH, Kang DH, Lee JM, Shin NY, Jung WH, Choi JS, Jang DP, Kwon JS. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res. 2009;111(1-3):86-93. doi: 10.1016/j.schres.2009.03.036Yoo SY, Yeon S, Choi CH, Kang DH, Lee JM, Shin NY, Jung WH, Choi JS, Jang DP, Kwon JS. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res. 2009;111(1-3):86-93. doi: 10.1016/j.schres.2009.03.036Jensen JE, Miller J, Williamson PC, Neufeld RW, Menon RS, Malla A, Manchanda R, Schaefer B, Densmore M, Drost DJ. Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry. 2004;184:409-415. doi: 10.1192/bjp.184.5.409Jensen JE, Miller J, Williamson PC, Neufeld RW, Menon RS, Malla A, Manchanda R, Schaefer B, Densmore M, Drost DJ. Focal changes in brain energy and phospholipid metabolism in first-episode schizophrenia: 31P-MRS chemical shift imaging study at 4 Tesla. Br J Psychiatry. 2004;184:409-415. doi: 10.1192/bjp.184.5.409Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, Kaprio J, Lönnqvist J, O’Neill J, Cannon TD. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15(3):308-318. doi:10.1038/mp.2008.87Lutkenhoff ES, van Erp TG, Thomas MA, Therman S, Manninen M, Huttunen MO, Kaprio J, Lönnqvist J, O’Neill J, Cannon TD. Proton MRS in twin pairs discordant for schizophrenia. Mol Psychiatry. 2010;15(3):308-318. doi:10.1038/mp.2008.87Wood SJ, Berger GE, Wellard RM, Proffitt T, McConchie M, Velakoulis D, McGorry PD, Pantelis C. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. Schizophr Res. 2008;102(1-3):163-170. doi: 10.1016/j.schres.2008.03.012Wood SJ, Berger GE, Wellard RM, Proffitt T, McConchie M, Velakoulis D, McGorry PD, Pantelis C. A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. Schizophr Res. 2008;102(1-3):163-170. doi: 10.1016/j.schres.2008.03.012Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res. 2001;52(1-2):87-99. doi: 10.1016/s0920-9964(01)00155-4Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr Res. 2001;52(1-2):87-99. doi: 10.1016/s0920-9964(01)00155-4Keshavan MS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study. Schizophr Res. 2009;115(1):88-93. doi: 10.1016/j.schres.2009.08.012Keshavan MS, Dick RM, Diwadkar VA, Montrose DM, Prasad KM, Stanley JA. Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a (1)H spectroscopy study. Schizophr Res. 2009;115(1):88-93. doi: 10.1016/j.schres.2009.08.012Deicken RF, Calabrese G, Merrin EL, Meyerhoff DJ, Dillon WP, Weiner MW, Fein G. 31-phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry. 1994;36(8):503-510. doi: 10.1016/0006-3223(94)90613-0.Deicken RF, Calabrese G, Merrin EL, Meyerhoff DJ, Dillon WP, Weiner MW, Fein G. 31-phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry. 1994;36(8):503-510. doi: 10.1016/0006-3223(94)90613-0.Frey BN, Stanley JA, Nery FG, Monkul ES, Nicoletti MA, Chen HH, Hatch JP, Caetano SC, Ortiz O, Kapczinski F, Soares JC. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study. Bipolar Disord. 2007; 9 Suppl 1:119127. doi: 10.1111/j.1399-5618.2007.00454.xFrey BN, Stanley JA, Nery FG, Monkul ES, Nicoletti MA, Chen HH, Hatch JP, Caetano SC, Ortiz O, Kapczinski F, Soares JC. Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo 1H MRS study. Bipolar Disord. 2007; 9 Suppl 1:119127. doi: 10.1111/j.1399-5618.2007.00454.xCecil KM, DelBello MP, Sellars MC, Strakowski SM. Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. J Child Adolesc Psychopharmacol. 2003;13(4):545-555. doi: 10.1089/104454603322724931.Cecil KM, DelBello MP, Sellars MC, Strakowski SM. Proton magnetic resonance spectroscopy of the frontal lobe and cerebellar vermis in children with a mood disorder and a familial risk for bipolar disorders. J Child Adolesc Psychopharmacol. 2003;13(4):545-555. doi: 10.1089/104454603322724931.Murashita J, Kato T, Shioiri T, Inubushi T, Kato N. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31PMR spectroscopy. Psychol Med. 2000;30(1):107-115. doi: 10.1017/s0033291799001439Murashita J, Kato T, Shioiri T, Inubushi T, Kato N. Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31PMR spectroscopy. Psychol Med. 2000;30(1):107-115. doi: 10.1017/s0033291799001439Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta. 2006; 1762(2):164-180. doi: 10.1016/j.bbadis.2005.09.004Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim Biophys Acta. 2006; 1762(2):164-180. doi: 10.1016/j.bbadis.2005.09.004Tachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci. 2004;20(1):144-160. doi: 10.1111/j.1460-9568.2004.03478.xTachikawa M, Fukaya M, Terasaki T, Ohtsuki S, Watanabe M. Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCK-Mi and CK-B suggest a novel neuron-glial relationship for brain energy homeostasis. Eur J Neurosci. 2004;20(1):144-160. doi: 10.1111/j.1460-9568.2004.03478.xTokarska-Schlattner M, Epand RF, Meiler F, Zandomeneghi G, Neumann D, Widmer HR, Meier BH, Epand RM, Saks V, Wallimann T, Schlattner U. Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects. PLoS One. 2012;7(8):e43178. doi: 10.1371/journal.pone.0043178Tokarska-Schlattner M, Epand RF, Meiler F, Zandomeneghi G, Neumann D, Widmer HR, Meier BH, Epand RM, Saks V, Wallimann T, Schlattner U. Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects. PLoS One. 2012;7(8):e43178. doi: 10.1371/journal.pone.0043178Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience. 2001;103(2):373-383. doi: 10.1016/s0306-4522(00)00580-7.Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience. 2001;103(2):373-383. doi: 10.1016/s0306-4522(00)00580-7.Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry. 2006;11(5):459-470, 423. doi: 10.1038/sj.mp.4001806Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry. 2006;11(5):459-470, 423. doi: 10.1038/sj.mp.4001806Clark D, Dedova I, Cordwell S, Matsumoto I. Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia. Proteomics Clin Appl. 2007;1(2):157-166. doi: 10.1002/prca.200600541Clark D, Dedova I, Cordwell S, Matsumoto I. Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia. Proteomics Clin Appl. 2007;1(2):157-166. doi: 10.1002/prca.200600541Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl. 2007;1(10):1291-1305. doi: 10.1002/prca.200700230Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl. 2007;1(10):1291-1305. doi: 10.1002/prca.200700230Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry. 2009;14(6):601-613. doi: 10.1038/mp.2008.7Behan AT, Byrne C, Dunn MJ, Cagney G, Cotter DR. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry. 2009;14(6):601-613. doi: 10.1038/mp.2008.7Burbaeva GSh, Savushkina OK, Boksha IS. Comparative study of creatine kinase BB decrease in brain of patients with Alzheimer’s disease and schizophrenia. Creatine kinase and brain energy metabolism: function and disease. NATO Science Series, IOS Press; Netherlands. 2003;125-132.Burbaeva GSh, Savushkina OK, Boksha IS. Comparative study of creatine kinase BB decrease in brain of patients with Alzheimer’s disease and schizophrenia. Creatine kinase and brain energy metabolism: function and disease. NATO Science Series, IOS Press; Netherlands. 2003;125-132.Савушкина ОК, Терешкина ЕБ, Прохорова ТА, Воробьева ЕА, Бокша ИС, Бурбаева ГШ. Распределение изоформы В креатинкиназы в мозге при шизофрении. Журнал неврологии и психиатрии им. C.C. Корсакова. 2016;116(9):62-68.Savushkina OK, Tereshkina EB, Prokhorova TA, Vorobeva EA, Boksha IS, Burbaeva GSh. Creatine kinase isoform B distribution in the brain in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(9):62-68. (In Russ.). doi: 10.17116/jnevro20161169162-68Бурбаева ГШ, Аксенова МВ, Бибикова ВИ. Активность ВВ-креатифосфокиназы в некоторых структурах мозга у психически здоровых людей и больных шизофренией. Журнал неврологии и психиатрии им. C.C. Корсакова. 1987;7:1024-1028.Burbaeva GSh, Aksenova MV, Bibikova VI. Aktivnost’ VV-kreatifosfokinazy v nekotoryh strukturah mozga u psihicheski zdorovyh ljudej i bol’nyh shizofreniej. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 1987;7:1024-1028. (In Russ.)Klushnik TP, Spunde AYa, Yakovlev AG, Khuchua ZA, Saks VA, Vartanyan ME. Intracellular alterations of the creatine kinase isoforms in brains of schizophrenic patients. Mol Chem Neuropathol. 1991;15(3):271-280. doi: 10.1007/BF03161065. PMID: 1807268.Klushnik TP, Spunde AYa, Yakovlev AG, Khuchua ZA, Saks VA, Vartanyan ME. Intracellular alterations of the creatine kinase isoforms in brains of schizophrenic patients. Mol Chem Neuropathol. 1991;15(3):271-280. doi: 10.1007/BF03161065. PMID: 1807268.Du F, Cooper AJ, Thida T, Sehovic S, Lukas SE, Cohen BM, Zhang X, Ongür D. In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy. JAMA Psychiatry. 2014;71(1):19-27. doi: 10.1001/jamapsychiatry.2013.2287Du F, Cooper AJ, Thida T, Sehovic S, Lukas SE, Cohen BM, Zhang X, Ongür D. In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using 31P magnetization transfer spectroscopy. JAMA Psychiatry. 2014;71(1):19-27. doi: 10.1001/jamapsychiatry.2013.2287Song X, Chen X, Yuksel C, Yuan J, Pizzagalli DA, Forester B, Öngür D, Du F. Bioenergetics and abnormal functional connectivity in psychotic disorders. Mol Psychiatry. 2021; 26(6):2483-2492. doi: 10.1038/s41380-020-00993-zSong X, Chen X, Yuksel C, Yuan J, Pizzagalli DA, Forester B, Öngür D, Du F. Bioenergetics and abnormal functional connectivity in psychotic disorders. Mol Psychiatry. 2021; 26(6):2483-2492. doi: 10.1038/s41380-020-00993-zMacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi C. Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 2006; 8(3):255-264. doi: 10.1111/j.1399-5618.2006.00302.xMacDonald ML, Naydenov A, Chu M, Matzilevich D, Konradi C. Decrease in creatine kinase messenger RNA expression in the hippocampus and dorsolateral prefrontal cortex in bipolar disorder. Bipolar Disord. 2006; 8(3):255-264. doi: 10.1111/j.1399-5618.2006.00302.xStreijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, Van der Zee CE. Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav Brain Res. 2005;157(2):219-234. doi: 10.1016/j.bbr.2004.07.002Streijger F, Oerlemans F, Ellenbroek BA, Jost CR, Wieringa B, Van der Zee CE. Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behav Brain Res. 2005;157(2):219-234. doi: 10.1016/j.bbr.2004.07.002Taylor JR, Abichandani L. Creatine phosphokinase elevations and psychiatric symptomatology. Biol Psychiatry. 1980;15(6):865-870. PMID: 7459407.Taylor JR, Abichandani L. Creatine phosphokinase elevations and psychiatric symptomatology. Biol Psychiatry. 1980;15(6):865-870. PMID: 7459407.Hollander S, Hochman E, Shoval G, Taler M, Trommer S, Hermesh H, Weizman A, Krivoy A. The association between serum creatine kinase, mood and psychosis in inpatients with schizophrenia, bipolar and schizoaffective disorders. Psychiatry Res. 2016;238:333-337. doi: 10.1016/j.psychres.2016.01.058Hollander S, Hochman E, Shoval G, Taler M, Trommer S, Hermesh H, Weizman A, Krivoy A. The association between serum creatine kinase, mood and psychosis in inpatients with schizophrenia, bipolar and schizoaffective disorders. Psychiatry Res. 2016;238:333-337. doi: 10.1016/j.psychres.2016.01.058Meng XD, Cao X, Li T, Li JP. Creatine kinase (CK) and its association with aggressive behavior in patients with schizophrenia. Schizophr Res. 2018; 197:478-483. doi: 10.1016/j.schres.2018.02.025Meng XD, Cao X, Li T, Li JP. Creatine kinase (CK) and its association with aggressive behavior in patients with schizophrenia. Schizophr Res. 2018; 197:478-483. doi: 10.1016/j.schres.2018.02.025Бурбаева ГШ, Савушкина ОК, Дмитриев АВ. Активность мозговой креатинфосфокиназы в норме и при писихических заболеваниях (болезнь Альцгеймера, шизофрения). Вестник Российской академии медицинских наук. 1999;1:20-24.Burbaeva GSh, Savushkina OK, Dmitriev AV. Aktivnost’ mozgovoi kreatinfosfokinazy v norme i pri pisikhicheskikh zabolevaniiakh (bolezn’ Al’tsgeimera, shizofreniia). Vestnik Rossiiskoi akademii medetsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 1999;1:20-24. (In Russ.).Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, Nakataki M, Ueno S, Harada M, Ohmori T. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108(1-3):69-77. doi: 10.1016/j.schres.2008.11.014Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, Nakataki M, Ueno S, Harada M, Ohmori T. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS). Schizophr Res. 2009;108(1-3):69-77. doi: 10.1016/j.schres.2008.11.014Lugenbiel P, Sartorius A, Vollmayr B, Schloss P. Creatine transporter expression after antidepressant therapy in rats bred for learned helplessness. World J Biol Psychiatry. 2010;11(2 Pt 2):329-333. doi: 10.1080/15622970903131597Lugenbiel P, Sartorius A, Vollmayr B, Schloss P. Creatine transporter expression after antidepressant therapy in rats bred for learned helplessness. World J Biol Psychiatry. 2010;11(2 Pt 2):329-333. doi: 10.1080/15622970903131597Agostinho FR, Scaini G, Ferreira GK, Jeremias IC, Réus GZ, Rezin GT, Castro AA, Zugno AI, Quevedo J, Streck EL. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull. 2009;80(6):337-340. doi: 10.1016/j.brainresbull.2009.09.002Agostinho FR, Scaini G, Ferreira GK, Jeremias IC, Réus GZ, Rezin GT, Castro AA, Zugno AI, Quevedo J, Streck EL. Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. Brain Res Bull. 2009;80(6):337-340. doi: 10.1016/j.brainresbull.2009.09.002Kim SY, Lee YJ, Kim H, Lee DW, Woo DC, Choi CB, Chae JH, Choe BY. Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: an in vivo(1)H-MRS study at 9.4T. Brain Res. 2010;1348:105-113. doi: 10.1016/j.brainres.2010.05.097Kim SY, Lee YJ, Kim H, Lee DW, Woo DC, Choi CB, Chae JH, Choe BY. Desipramine attenuates forced swim test-induced behavioral and neurochemical alterations in mice: an in vivo(1)H-MRS study at 9.4T. Brain Res. 2010;1348:105-113. doi: 10.1016/j.brainres.2010.05.097Réus GZ, Stringari RB, Gonçalves CL, Scaini G, Carvalho-Silva M, Jeremias GC, Jeremias IC, Ferreira GK, Streck EL, Hallak JE, Zuardi AW, Crippa JA, Quevedo J. Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain. Depress Res Treat. 2012;2012:987397. doi: 10.1155/2012/987397Réus GZ, Stringari RB, Gonçalves CL, Scaini G, Carvalho-Silva M, Jeremias GC, Jeremias IC, Ferreira GK, Streck EL, Hallak JE, Zuardi AW, Crippa JA, Quevedo J. Administration of harmine and imipramine alters creatine kinase and mitochondrial respiratory chain activities in the rat brain. Depress Res Treat. 2012;2012:987397. doi: 10.1155/2012/987397Assis LC, Scaini G, Di-Pietro PB, Castro AA, Comim CM, Streck EL, Quevedo J. Effect of antipsychotics on creatine kinase activity in rat brain. Basic Clin Pharmacol Toxicol. 2007;101(5):315-319. doi: 10.1111/j.1742-7835.2007.00128.xAssis LC, Scaini G, Di-Pietro PB, Castro AA, Comim CM, Streck EL, Quevedo J. Effect of antipsychotics on creatine kinase activity in rat brain. Basic Clin Pharmacol Toxicol. 2007;101(5):315-319. doi: 10.1111/j.1742-7835.2007.00128.xAllen PJ, D’Anci KE, Kanarek RB, Renshaw PF. Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats. Pharmacol Biochem Behav. 2012;101(4):588-601. doi: 10.1016/j.pbb.2012.03.00Allen PJ, D’Anci KE, Kanarek RB, Renshaw PF. Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats. Pharmacol Biochem Behav. 2012;101(4):588-601. doi: 10.1016/j.pbb.2012.03.00Prokopidis K, Giannos P, Triantafyllidis KK, Kechagias KS, Forbes SC, Candow DG. Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023;81(4):416-427. doi: 10.1093/nutrit/nuac064Prokopidis K, Giannos P, Triantafyllidis KK, Kechagias KS, Forbes SC, Candow DG. Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023;81(4):416-427. doi: 10.1093/nutrit/nuac064Gordji-Nejad A, Matusch A, Kleedörfer S, Jayeshkumar Patel H, Drzezga A, Elmenhorst D, Binkofski F, Bauer A. Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Sci Rep. 2024;14(1):4937. doi: 10.1038/s41598-024-54249-9Gordji-Nejad A, Matusch A, Kleedörfer S, Jayeshkumar Patel H, Drzezga A, Elmenhorst D, Binkofski F, Bauer A. Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation. Sci Rep. 2024;14(1):4937. doi: 10.1038/s41598-024-54249-9Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, crossover trial. Proc Biol Sci. 2003;270(1529):2147-2150. doi: 10.1098/rspb.2003.2492Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, crossover trial. Proc Biol Sci. 2003;270(1529):2147-2150. doi: 10.1098/rspb.2003.2492McMorris T, Harris RC, Swain J, Corbett J, Collard K, Dyson RJ, Dye L, Hodgson C, Draper N. Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology (Berl). 2006;185(1):93-103. doi: 10.1007/s00213-005-0269-zMcMorris T, Harris RC, Swain J, Corbett J, Collard K, Dyson RJ, Dye L, Hodgson C, Draper N. Effect of creatine supplementation and sleep deprivation, with mild exercise, on cognitive and psychomotor performance, mood state, and plasma concentrations of catecholamines and cortisol. Psychopharmacology (Berl). 2006;185(1):93-103. doi: 10.1007/s00213-005-0269-zMcMorris T, Mielcarz G, Harris RC, Swain JP, Howard A. Creatine supplementation and cognitive performance in elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14(5):517-528. doi: 10.1080/13825580600788100.McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A. Creatine supplementation and cognitive performance in elderly individuals. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2007;14(5):517-528. doi: 10.1080/13825580600788100.Bianchi MC, Tosetti M, Battini R, Leuzzi V, Alessandri’ MG, Carducci C, Antonozzi I, Cioni G. Treatment monitoring of brain creatine deficiency syndromes: a 1H- and 31P-MR spectroscopy study. AJNR Am J Neuroradiol. 2007;28(3):548-554. PMID: 17353334; PMCID: PMC7977852.Bianchi MC, Tosetti M, Battini R, Leuzzi V, Alessandri’ MG, Carducci C, Antonozzi I, Cioni G. Treatment monitoring of brain creatine deficiency syndromes: a 1H- and 31P-MR spectroscopy study. AJNR Am J Neuroradiol. 2007;28(3):548-554. PMID: 17353334; PMCID: PMC7977852.Shi K, Zhao H, Xu S, Han H, Li W. Treatment efficacy of high-dose creatine supplementation in a child with creatine transporter (SLC6A8) deficiency. Mol Genet Genomic Med. 2021;9(4):e1640. doi: 10.1002/mgg3.1640Shi K, Zhao H, Xu S, Han H, Li W. Treatment efficacy of high-dose creatine supplementation in a child with creatine transporter (SLC6A8) deficiency. Mol Genet Genomic Med. 2021;9(4):e1640. doi: 10.1002/mgg3.1640Koga Y, Takahashi H, Oikawa D, Tachibana T, Denbow DM, Furuse M. Brain creatine functions to attenuate acute stress responses through GABAnergic system in chicks. Neuroscience. 2005;132(1):65-71. doi: 10.1016/j.neuroscience.2005.01.004Koga Y, Takahashi H, Oikawa D, Tachibana T, Denbow DM, Furuse M. Brain creatine functions to attenuate acute stress responses through GABAnergic system in chicks. Neuroscience. 2005;132(1):65-71. doi: 10.1016/j.neuroscience.2005.01.004Toniolo RA, Fernandes FBF, Silva M, Dias RDS, Lafer B. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2017; 224:69-75. doi: 10.1016/j.jad.2016.11.029Toniolo RA, Fernandes FBF, Silva M, Dias RDS, Lafer B. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: Results from a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2017; 224:69-75. doi: 10.1016/j.jad.2016.11.029Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF. Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. J Dual Diagn. 2015;11(3-4):189-202. doi: 10.1080/15504263.2015.1100471Hellem TL, Sung YH, Shi XF, Pett MA, Latendresse G, Morgan J, Huber RS, Kuykendall D, Lundberg KJ, Renshaw PF. Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. J Dual Diagn. 2015;11(3-4):189-202. doi: 10.1080/15504263.2015.1100471Smith AN, Morris JK, Carbuhn AF, Herda TJ, Keller JE, Sullivan DK, Taylor MK. Creatine as a Therapeutic Target in Alzheimer’s Disease. Curr Dev Nutr. 2023;7(11):102011. doi: 10.1016/j.cdnut.2023.102011Smith AN, Morris JK, Carbuhn AF, Herda TJ, Keller JE, Sullivan DK, Taylor MK. Creatine as a Therapeutic Target in Alzheimer’s Disease. Curr Dev Nutr. 2023;7(11):102011. doi: 10.1016/j.cdnut.2023.102011Taylor MK, Burns JM, Choi IY, Herda TJ, Lee P, Smith AN, Sullivan DK, Swerdlow RH, Wilkins HM. Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer’s disease. Pilot Feasibility Stud. 2024;10(1):42. doi: 10.1186/s40814-024-01469-5Taylor MK, Burns JM, Choi IY, Herda TJ, Lee P, Smith AN, Sullivan DK, Swerdlow RH, Wilkins HM. Protocol for a single-arm, pilot trial of creatine monohydrate supplementation in patients with Alzheimer’s disease. Pilot Feasibility Stud. 2024;10(1):42. doi: 10.1186/s40814-024-01469-5Mabondzo A, Harati R, Broca-Brisson L, Guyot AC, Costa N, Cacciante F, Putignano E, Baroncelli L, Skelton MR, Saab C, Martini E, Benech H, Joudinaud T, Gaillard JC, Armengaud J, Hamoudi R. Dodecyl creatine ester improves cognitive function and identifies key protein drivers including KIF1A and PLCB1 in a mouse model of creatine transporter deficiency. Front Mol Neurosci. 2023;16:1118707. doi: 10.3389/fnmol.2023.1118707Mabondzo A, Harati R, Broca-Brisson L, Guyot AC, Costa N, Cacciante F, Putignano E, Baroncelli L, Skelton MR, Saab C, Martini E, Benech H, Joudinaud T, Gaillard JC, Armengaud J, Hamoudi R. Dodecyl creatine ester improves cognitive function and identifies key protein drivers including KIF1A and PLCB1 in a mouse model of creatine transporter deficiency. Front Mol Neurosci. 2023;16:1118707. doi: 10.3389/fnmol.2023.1118707Zhang W, Zhang H, Xing Y. Protective effects of phosphocreatine administered post-treatment combined with ischemic post-conditioning on rat hearts with myocardial ischemia/reperfusion injury. J Clin Med Res. 2015;7(4):242-247. doi: 10.14740/jocmr2087wZhang W, Zhang H, Xing Y. Protective effects of phosphocreatine administered post-treatment combined with ischemic post-conditioning on rat hearts with myocardial ischemia/reperfusion injury. J Clin Med Res. 2015;7(4):242-247. doi: 10.14740/jocmr2087wКежун Л. В. Кардиометаболическая терапия при COVID-19 инфекции. Медицинские новости. 2021;9:30-34.Kezhun LV. Сardiometabolic therapy for COVID-19 infection. Meditsinskie novosti. 2021;9:30-34. (In Russ.).Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull. 2008; 76(4):329-343. doi: 10.1016/j.brainresbull.2008.02.035Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull. 2008; 76(4):329-343. doi: 10.1016/j.brainresbull.2008.02.035Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40(5):837-849. doi: 10.1016/j.freeradbiomed.2005.10.035.Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40(5):837-849. doi: 10.1016/j.freeradbiomed.2005.10.035.

The authors declare that there are no conflicts of interest present.